niacin has been researched along with Chronic Kidney Failure in 16 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Niacin has profound and unique effects on lipid metabolism." | 5.36 | Niacin as potential treatment for dyslipidemia and hyperphosphatemia associated with chronic renal failure: the need for clinical trials. ( Ahmed, MH, 2010) |
| "Hyperphosphatemia is an important modifiable risk factor in the dialysis population because it is linked to increased mortality." | 2.45 | Niacin and analogs for phosphate control in dialysis--perspective from a developing country. ( Sampathkumar, K, 2009) |
| "The evidence to support treating dyslipidemia in hemodialysis patients, however, has been mixed, with several outcome trials pending." | 2.44 | Managing dyslipidemia in chronic kidney disease. ( Harper, CR; Jacobson, TA, 2008) |
| "Niacin has profound and unique effects on lipid metabolism." | 1.36 | Niacin as potential treatment for dyslipidemia and hyperphosphatemia associated with chronic renal failure: the need for clinical trials. ( Ahmed, MH, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (18.75) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Kędzierska-Kapuza, K | 1 |
| Szczuko, U | 1 |
| Stolińska, H | 1 |
| Bakaloudi, DR | 1 |
| Wierzba, W | 1 |
| Szczuko, M | 1 |
| Streja, E | 1 |
| Streja, DA | 1 |
| Soohoo, M | 1 |
| Kleine, CE | 1 |
| Hsiung, JT | 1 |
| Park, C | 1 |
| Moradi, H | 1 |
| Rennick, A | 1 |
| Kalakeche, R | 1 |
| Seel, L | 1 |
| Shepler, B | 1 |
| Wahawisan, J | 1 |
| Tovar, JM | 1 |
| Granberry, MC | 1 |
| Harper, CR | 1 |
| Jacobson, TA | 1 |
| Sampathkumar, K | 2 |
| Cho, KH | 2 |
| Kim, HJ | 2 |
| Rodriguez-Iturbe, B | 1 |
| Vaziri, ND | 2 |
| Kamanna, VS | 1 |
| Ahmed, MH | 1 |
| Ix, JH | 1 |
| Ganjoo, P | 1 |
| Tipping, D | 1 |
| Tershakovec, AM | 1 |
| Bostom, AG | 1 |
| Selvam, M | 1 |
| Sooraj, YS | 1 |
| Gowthaman, S | 1 |
| Ajeshkumar, RN | 1 |
| Saika, Y | 1 |
| Kodama, N | 1 |
| Kimura, K | 1 |
| Fujii, R | 1 |
| Ohtani, H | 1 |
| Mune, M | 1 |
| Mimura, K | 1 |
| Maeda, T | 1 |
| Yukawa, S | 1 |
| Grundy, SM | 1 |
| Ramirez, G | 2 |
| Chen, M | 2 |
| Boyce, HW | 2 |
| Fuller, SM | 2 |
| Ganguly, R | 1 |
| Brueggemeyer, CD | 2 |
| Butcher, DE | 2 |
| Newton, JL | 1 |
| Stein, G | 1 |
| Sperschneider, H | 1 |
| Koppe, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy and Safety of Niacin on Hyperphosphatemia in End Stage Renal Disease Patients Undergoing Haemodialysis[NCT03163576] | Phase 4 | 150 participants (Anticipated) | Interventional | 2017-06-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for niacin and Chronic Kidney Failure
| Article | Year |
|---|---|
Demand for Water-Soluble Vitamins in a Group of Patients with CKD versus Interventions and Supplementation-A Systematic Review.
Topics: Ascorbic Acid; Dietary Supplements; Folic Acid; Humans; Kidney Failure, Chronic; Niacin; Renal Dialy | 2023 |
Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Fenofibrate; Humans; Hy | 2018 |
Nicotinic acid and nicotinamide: a review of their use for hyperphosphatemia in dialysis patients.
Topics: Animals; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Niacin; Niacinamide; Peritoneal Dialysi | 2013 |
Managing dyslipidemia in chronic kidney disease.
Topics: Algorithms; Anticholesteremic Agents; Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Fatty | 2008 |
Niacin and analogs for phosphate control in dialysis--perspective from a developing country.
Topics: Administration, Oral; Clinical Trials as Topic; Cost Savings; Developing Countries; Dose-Response Re | 2009 |
Management of hyperlipidemia of kidney disease.
Topics: Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolem | 1990 |
1 trial available for niacin and Chronic Kidney Failure
| Article | Year |
|---|---|
Extended release nicotinic acid - a novel oral agent for phosphate control.
Topics: Adult; Aged; Alkaline Phosphatase; Calcium; Delayed-Action Preparations; Female; Humans; Hypolipidem | 2006 |
9 other studies available for niacin and Chronic Kidney Failure
| Article | Year |
|---|---|
Statin therapy: when to think twice.
Topics: Cardiovascular Diseases; Contraindications; Drug Therapy, Combination; Heart Failure; Humans; Hydrox | 2013 |
Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure.
Topics: Animals; Chemokine CCL2; Creatinine; Disease Models, Animal; Hypertension; Inflammation; Kidney Fail | 2009 |
Niacin improves renal lipid metabolism and slows progression in chronic kidney disease.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Basic Helix-Loop-Hel | 2010 |
Niacin as potential treatment for dyslipidemia and hyperphosphatemia associated with chronic renal failure: the need for clinical trials.
Topics: Clinical Trials as Topic; Dyslipidemias; Humans; Hyperphosphatemia; Hypolipidemic Agents; Kidney Fai | 2010 |
Sustained hypophosphatemic effect of once-daily niacin/laropiprant in dyslipidemic CKD stage 3 patients.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Dyslipide | 2011 |
[Plasma nicotinic acid levels in hemodialysis patients after the administration of niceritrol].
Topics: Arteriosclerosis; Humans; Hypolipidemic Agents; Kidney Failure, Chronic; Lipoprotein(a); Niacin; Nic | 1999 |
Longitudinal follow-up of chronic hemodialysis patients without vitamin supplementation.
Topics: Adult; Aged; Ascorbic Acid; Female; Folic Acid; Follow-Up Studies; Humans; Kidney Failure, Chronic; | 1986 |
The plasma and red cell vitamin B levels of chronic hemodialysis patients: a longitudinal study.
Topics: Adult; Aged; Erythrocytes; Female; Folic Acid; Humans; Kidney Failure, Chronic; Longitudinal Studies | 1986 |
Vitamin levels in chronic renal failure and need for supplementation.
Topics: Ascorbic Acid; Avitaminosis; Biotin; Folic Acid; Humans; Kidney Failure, Chronic; Niacin; Pantotheni | 1985 |